# US 2019/0241521 A1 · Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0241521 A1
- Document ID: US20190241521A1
- Status: Published application
- Kind: A1
- Application number: 16/340,151
- Filed: 2017-10-18
- Published: 2019-08-08
- Earliest claimed: 2016-10-25
- Assignees: Boehringer Ingelheim International GmbH
- Applicants: Boehringer Ingelheim International GmbH
- Inventors: Matthias ECKHARDT; Stefan PETERS; Holger WAGNER
- Web page: https://patentgrep.com/patent/US20190241521A1

## CPC

- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of general formula I, wherein the groups R, R1, R2, R3, m and n are defined herein, which have valuable pharmacological properties, including binding to the GPR40 receptor and modulating its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2. Furthermore, the invention relates to novel intermediates, useful for the synthesis of compounds of formula I.

## Claims

### Claim 1

A compound of formula (I)
wherein
R is selected from the group consisting of
H, F, Cl, Br, I, C1-6-alkyl, C2-6-alkenyl, C2-6-alkynyl, C3-6-cycloalkyl, NC—, HNRN—C(═O)—, C1-4-alkyl-NRN—C(═O)—, C3-6-cycloalkyl-NRN—C(═O)—, heterocyclyl-NRN—C(═O)—, heteroaryl-NRN—C(═O)—, HOOC—, C1-4-alkyl-O—C(═O)—, O2N—, HRNN—, C1-4-alkyl-RNN—, C1-4-alkyl-C(═O)NRN—, C3-6-cycloalkyl-C(═O)NRN—, heterocyclyl-C(═O)NRN—, heteroaryl-C(═O)NRN—, C1-4-alkyl-S(═O)2NRN—, C3-6-cycloalkyl-S(═O)2NRN—, heterocyclyl-S(═O)2NRN—, heteroaryl-S(═O)2NRN—, HO—, C1-6-alkyl-O—, HOOC—C1-3-alkyl-O—, C3-6-cycloalkyl-C1-3-alkyl-O—, heterocyclyl-C1-3-alkyl-O—, phenyl-C1-3-alkyl-O—, C3-6-cycloalkyl-O—, heterocyclyl-O—, heteroaryl-O—, C1-4-alkyl-S—, C3-6-cycloalkyl-S—, heterocyclyl-S—, C1-4-alkyl-S(═O)—, C3-6-cycloalkyl-S(═O)—, heterocyclyl-S(═O)—, C1-4-alkyl-S(═O)2—, C3-6-cycloalkyl-S(═O)2—, heterocyclyl-S(═O)2—, phenyl-S(═O)2—, heteroaryl-S(═O)2—, HNRN—S(═O)2—, C1-4-alkyl-NRN—S(═O)2—, heterocyclyl, phenyl, and heteroaryl,
wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups forming R is optionally substituted with 1 or more F atoms and optionally substituted with 1 to 3 groups independently selected from Cl, C1-3-alkyl, NC—, (RN)2N—, HO—, C1-3-alkyl-O—, and C1-3-alkyl-S(═O)2—; and
wherein each phenyl and heteroaryl group or sub-group within the groups forming R is optionally substituted with 1 to 5 substituents independently selected from F, Cl, C1-3-alkyl, HF2C—, F3C—, NC—, (RN)2N—, HO—, C1-3-alkyl-O—, F3C—O—, and C1-3-alkyl-S(═O)2—;
wherein each heterocyclyl group or sub-group within the groups forming R is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NRN— or —O—;
a C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —C(═O)—, —NRN—, —O—, —S— or —S(═O)2— and/or 1 CH group is replaced by N;
a C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —NRN— or —O—, a second CH2 group is replaced by —NRN—, —C(═O)— or —S(═O)2— and/or 1 CH group is replaced by N; and
a C5-6-cycloalkyl group wherein 2 CH2 groups are replaced by —NRN— or 1 CH2 group by —NRN— and the other by —O— and a third CH2 group is replaced by —C(═O)— or —S(═O)2— and/or 1 CH group is replaced by N;
wherein each heteroaryl group or sub-group within the groups forming R is selected from tetrazolyl and a 5- or 6-membered heteroaromatic ring which contains 1, 2, or 3 heteroatoms independently of each other selected from ═N—, —NRN—, —O—, and —S—, wherein in heteroaromatic groups containing a —HC═N— unit this group is optionally replaced by —NRN—C(═O)—;
wherein in heteroaryl and heterocyclyl rings with one or more NH groups, each of said NH groups is replaced by NRN;
R1 is selected from the group consisting of H, F, Cl, C1-4-alkyl, C3-6-cycloalkyl-, HO—C1-4-alkyl, C1-4-alkyl-O—C1-4-alkyl, NC—, HO—, C1-4-alkyl-O—, C3-6-cycloalkyl-O—, C1-4-alkyl-S—, C1-4-alkyl-S(O)—, and C1-4-alkyl-S(O)2—,
wherein any alkyl and cycloalkyl group or sub-group within the groups forming R1 is optionally substituted with 1 or more F atoms, and wherein multiple R1 may be identical or different if m is 2, 3 or 4;
m is an integer selected from 1, 2, 3, and 4;
R2 is selected from the group consisting of H, F, Cl, C1-4-alkyl, NC—, and C1-4-alkyloxy,
wherein any alkyl group or sub-group within the groups forming R2 is optionally substituted with 1 or more F atoms, and wherein multiple R2 may be identical or different if n is 2 or 3;
R3 is selected from the group consisting of H, F, Cl, C1-4-alkyl, NC—, and C1-4-alkyl-O—,
wherein each alkyl group or sub-group within the groups forming R3 is optionally substituted with 1 or more F atoms;
n is an integer selected from 1, 2, and 3;
RN is independently of each other selected from the group consisting of H, C1-4-alkyl, HO—C1-4-alkyl-(H2C)—, C1-3-alkyl-O—C1-4-alkyl-, C1-4-alkyl-C(═O)—, C1-4-alkyl-NH—C(═O)—, C1-4-alkyl-N(C1-4-alkyl)-C(═O)—, C1-4-alkyl-O—C(═O)—, and C1-4-alkyl-S(═O)2—,
wherein each alkyl group or sub-group within the groups forming RN is optionally substituted with 1 or more F atoms;
wherein in any definition mentioned hereinbefore, if not specified otherwise, any alkyl group or sub-group may be straight-chained or branched,
or a salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein
R is selected from the group consisting of H, F, Cl, C1-6-alkyl, C3-6-cycloalkyl, NC—, HNRN—C(═O)—, C1-4-alkyl-NRN—C(═O)—, C3-6-cycloalkyl-NRN—C(═O)—, heterocyclyl-NRN—C(═O)—, HOOC—, HRNN—, C1-4-alkyl-RNN—, C1-4-alkyl-C(═O)NRN—, C3-6-cycloalkyl-C(═O)NRN—, heterocyclyl-C(═O)NRN—, C1-4-alkyl-S(═O)2NRN—, HO—, C1-6-alkyl-O—, HOOC—(C1-2-alkyl)-O—, cyclopropyl-H2C—O—, heterocyclyl-C1-2-alkyl-O—, phenyl-C1-2-alkyl-O—, C3-6-cycloalkyl-O—, heterocyclyl-O—, heteroaryl-O—, C1-4-alkyl-S(═O)2—, C3-6-cycloalkyl-S(═O)2—, heterocyclyl-S(═O)2—, HNRN—S(═O)2—, C1-4-alkyl-NRN—S(═O)2—, heterocyclyl, and heteroaryl,
wherein each alkyl, cycloalkyl, and heterocyclyl group or sub-group within the groups forming R is optionally substituted with 1 or more F atoms and optionally substituted with 1 to 2 groups independently selected from Cl, H3C—, NC—, RNHN—, HO—, H3C—O—, and H3C—S(═O)2—;
wherein each heteroaryl group or sub-group within the groups forming R is optionally substituted with 1 to 3 substituents independently selected from F, Cl, H3C—, F3C—, NC—, (RN)2N—, HO—, H3C—O—, F3C—O—, and H3C—S(═O)2—;
wherein each heterocyclyl group or sub-group within the groups forming R is selected from
a cyclobutyl group wherein 1 CH2 group is replaced by —NRN— or —O—;
a C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —C(═O)—, —NRN—, —O—, —S— or —S(═O)2— and/or 1 CH group is replaced by N;
a C5-6-cycloalkyl group wherein 1 CH2 group is replaced by —NRN— or —O—, a second CH2 group is replaced by —NRN—, —C(═O)— or —S(═O)2— and/or 1 CH group is replaced by N;
wherein each heteroaryl group or sub-group within the groups forming R is selected from tetrazolyl, a 5-membered heteroaromatic ring which contains 1, 2 or 3 heteroatoms independently of each other selected from ═N—, —NH—, O and S, and a 6-membered heteroaromatic ring which contains 1 or 2 ═N— atoms, wherein a —HC═N— unit is optionally replaced by —NH—C(═O)—;
and wherein in each of the above heteroaryl and heterocyclyl group or sub-group containing one or more NH, said group(s) is replaced by NRN;
or a salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein
R is selected from the group consisting of H, F, Cl, NC—, H2NC(═O)—, H3CHN—C(═O)—, (H3C)2N—C(═O)—, HO—;
C1-3-alkyl is optionally substituted with 1 or more F or optionally monosubstituted with HO—;
cyclopropyl optionally monosubstituted with NC—;
H3C—O— optionally monosubstituted with C1-4-alkyl, HOOC—, oxetanyl, tetrahydro-furanyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, or phenyl,
wherein the C1-4-alkyl group optionally attached to H3C—O— is optionally monosubstituted with NC—, HO— or H3C—S(═O)2—, and
wherein said oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl and 1,1-dioxotetrahydrothiopyranyl groups are optionally monosubstituted with H3C— or HO—;
cyclopropyl-H2C—O—, cyclopropyl-O—, tetrahydrofuranyl-O— and tetrahydropyranyl-O—; and
a heteroaryl group selected from pyrazolyl, [1,2,4]oxadiazolyl, tetrazolyl, pyridyl, pyridin-2-onyl, pyrazinyl, pyrimidinyl, pyrimidin-2-onyl, and pyrimidin-4-onyl,
wherein each of said heteroaryl groups is optionally monosubstituted with H3C—, and
wherein each H—N group in said heteroaryl groups is optionally replaced with H3C—N or (H3C)2C(OH)—H2C—N,
and 2-methoxypyridin-4-yl;
or a salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein
R1 is H, F, Cl, H3C—, H3C—H2C—, (H3C)2HC—, F3C—, or H3C—O—;
m is 2;
R2 is H, F, or F3C—;
n is 1 or 2; and
R3 is H;
or a salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein R1 is H3C—; or a salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein R is selected from the group consisting of H, F, Cl, NC—, H2NC(═O)—, H3CHN—C(═O)—, (H3C)2N—C(═O)—, HO—;
C1-3-alkyl optionally substituted with 1 or more F or optionally monosubstituted with HO—;
cyclopropyl optionally monosubstituted with NC—;
H3C—O— optionally monosubstituted with C1-4-alkyl, HOOC—, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, 1,1-dioxotetrahydrothiopyranyl, or phenyl,
wherein the C1-4-alkyl group optionally attached to H3C—O— is optionally monosubstituted with NC—, HO— or H3C—S(═O)2—, and
wherein said oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl and 1,1-dioxotetrahydrothiopyranyl groups are optionally monosubstituted with H3C— or HO—;
cyclopropyl-H2C—O—, cyclopropyl-O—, tetrahydrofuranyl-O— and tetrahydropyranyl-O—; and
a heteroaryl group selected from pyrazolyl, [1,2,4]oxadiazolyl, tetrazolyl, pyridyl, pyridin-2-onyl, pyrazinyl, pyrimidinyl, pyrimidin-2-onyl, and pyrimidin-4-onyl,
wherein each of said heteroaryl groups is optionally monosubstituted with H3C—, and
wherein each H—N group in said heteroaryl groups is optionally replaced with H3C—N or (H3C)2C(OH)—H2C—N,
and 2-methoxypyridin-4-yl;
R1 is selected from the group consisting of H, F, Cl, H3C—, H3C—H2C—, (H3C)2HC—, F3C—, and H3C—O—;
m is 2;
R2 is selected from the group consisting of H, F, and F3C—;
n is 1 or 2; and
R3 is selected from the group consisting of H;
or a salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein R is selected from the group consisting of H, F, Cl, H3C—, H3C—H2C—, (H3C)2CH—,
F3C—, HOCH2—, NC—, H2N—C(═O)—, H3C—NH—C(═O)—, (H3C)2N—C(═O)—, H3C—O—, cyclopropyl-H2C—O—, F3C—O—, cyclopropyl-O—,
wherein the asterisk (-*) indicates the site/point of attachment;
R1 is selected from the group consisting of H3C—;
m is 2;
R2 is selected from the group consisting of H, F, and F3C—;
n is 1 or 2; and
R3 is selected from the group consisting of H;
or a salt thereof.

### Claim 8 (depends on 1)

The compound according to claim 1, with the structure and stereochemistry shown in formulae I.1, I.2, I.3, or I.4
or a salt thereof.

### Claim 9 (depends on 1)

A pharmaceutically acceptable salt of a compound according to claim 1.

### Claim 10 (depends on 1)

A pharmaceutical composition comprising one or more compounds according to claim 1 or one or more pharmaceutically acceptable salts thereof, optionally together with one or more inert carriers and/or diluents.

### Claim 11 (depends on 1)

A method for treating a disease or condition which can be influenced by the modulation of the function of GPR40, the method comprising administering to a patient in need thereof, a compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the disease or condition is a metabolic disease selected from type 2 diabetes mellitus, insulin resistance, obesity, cardiovascular disease and dyslipidemia.

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14 (depends on 1)

A pharmaceutical composition comprising one or more compounds according to claim 1 or one or more pharmaceutically acceptable salts thereof and one or more additional therapeutic agents, optionally together with one or more inert carriers and/or diluents.

### Claim 15 (depends on 14)

The pharmaceutical composition according to claim 14 wherein the one or more additional therapeutic agents is selected from the group consisting of antidiabetic agents, agents for the treatment of overweight and/or obesity and agents for the treatment of high blood pressure, heart failure and/or atherosclerosis.
